English
Italiano
Deutsch
日本語
中文
Español
Hilton Shenzhen Futian
Shenzhen, China
Are you interested in GLP-1 treatment? Do you have any doubts about it?
Stevanato Group and Datwyler Healthcare teamed up with BioValley to hold a GLP-1 city tour event, aiming to share insights around technological innovation, dedicated product solutions and collaboration opportunities for GLP-1.
Join us!
Benefiting from the expansion of the hypoglycemic and weight management markets, GLP-1 drugs have continuously broken new sales records in China in recent years. Many domestic pharmaceutical companies have also made GLP-1 biosimilars a development focus, which has driven the development of the entire industry chain from drug development to downstream formulation production, high-value consumables, pharmaceutical packaging materials. As a result, GLP-1 drugs and their entire industry chain have become a hot topic in the field of biopharmaceuticals.
We also well-known experts and business representatives in the industry to jointly discuss the current situation, challenges, and future development trends of the GLP-1 market.
Daniel Martinez - Product Management DCS & Analytical Services
As a one-stop solution provider, how can we support pharma companies across their entire GLP-1 portfolio? Daniel will illustrate you challenges and viable solutions from the very beginning of the drug lifecycle.
13:00-13:30
Guest sign in (signature photo)
13:30-13:40
Welcome speech
13:40-14:20
TBD
14:20-15:00
Technical challenges of elastomer components in GLP-1 drug injection packaging
By Qiu Sheng, China Business Development, Datwyler
15:00-15:40
GIP, GLP-1, FGF21 triple target agonists, ushering in a new era of MASH therapy
By Song Wenxin, Vice GM, CSO, Mingwei Biotechnology
15:40-16:10
Tea Break
16:10-16:50
GLP-1: Ensuring better performance, flexibility, and faster time to market with integrated solutions
By Daniel Martinez, Stevanato Group Product Manager for Syringes, Components, and Analytical Services
16:50-17:30
The specifications and key points of clinical application and BLA for GLP-1 class biological products in the United States
By Sun Dinghe, Senior Consultant for Biological Products, ELIQUENT
17:30
Group Photo